FRANKFURT (Reuters) - AstraZeneca said that it has no involvement in a planned clinical trial where volunteers would be given an experimental vaccine and then be deliberately infected with the new coronavirus, as reported by the Financial Times.
A company spokesman on Wednesday also ruled out that AstraZeneca’s experimental COVID-19 vaccine, which was initially developed by the University of Oxford, would play a role in the reported trial.
The FT said the so-called human challenge trial is expected to begin in January at a quarantine facility in London.
Reporting by Ludwig Burger. Editing by Jane Merriman
Our Standards: The Thomson Reuters Trust Principles.